Total raised
$3.0M
Last: Seed 2019-01
Stage
Seed
Founded
2017
Headcount
3
HQ
Sector
Health Tech & Life Sciences
About
Moya Bio is developing a novel class of tumor immune conditioning agents. The company's inhibitors of the FAT10 pathway are designed to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations. Moya Bio's translational data demonstrates a correlation between FAT10 down regulation, increased T-cell infiltration into the tumor microenvironment, and inhibition of tumor growth. The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.
Funding history · 1 round · $3.0M total
2019-01
Seed
$3.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
medical-technologiesimmunotherapyhospitalsbiotechnologycancerlife-sciences